Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Published Date: 26 Nov 2025

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot